Ascentage Pharma Group International (AAPG) Liabilities and Shareholders Equity (2023 - 2025)

Ascentage Pharma Group International (AAPG) has reported Liabilities and Shareholders Equity for 3 consecutive years, with $558.8 million the latest figure, recorded in Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 53.34% year-over-year to $558.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.7 billion (changed N/A YoY) and the FY2025 annual result came in at $551.5 million, up 51.34% from the prior year.
• Liabilities and Shareholders Equity climbed to $558.8 million in Q4 2025 per AAPG's latest filing, from $425.2 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for AAPG reached as high as $558.8 million in Q4 2025 and fell as low as $347.3 million in Q4 2023.
• A 3-year average of $423.9 million and a median of $394.8 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity gained 4.94% — and 2025, when it jumped 53.34%.
• Year by year, Liabilities and Shareholders Equity stood at $347.3 million in 2023, then increased by 4.94% to $364.4 million in 2024, then soared by 53.34% to $558.8 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $558.8 million, $425.2 million, and $364.4 million for Q4 2025, Q2 2025, and Q4 2024 respectively.